NIRVF (Nirvana Life Sciences) ROCE %: 0.00% (As of Jan. 2026)


What is Nirvana Life Sciences ROCE %?

Nirvana Life Sciences NIRVF ROCE % is 0.00% as of Jan. 2026. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nirvana Life Sciences's annualized ROCE % for the quarter that ended in Jan. 2026 was 0.00%.

Nirvana Life Sciences  (OTCPK:NIRVF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nirvana Life Sciences ROCE % Related Terms

Nirvana Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences ROCE % Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
ROCE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences ROCE % Calculation

Nirvana Life Sciences's annualized ROCE % for the fiscal year that ended in Apr. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=-0.262/( ( (0.015 - 0.847) + (0.014 - 1.079) )/ 2 )
=-0.262/( (-0.832+-1.065)/ 2 )
=-0.262/-0.9485
=27.62 %

Nirvana Life Sciences's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-0.152/( ( (0.015 - 0.424) + (0.015 - 0.467) )/ 2 )
=-0.152/( ( -0.409 + -0.452 )/ 2 )
=-0.152/-0.4305
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Nirvana Life Sciences (NIRVF) has a ROCE % of 0.00% as of Jan. 2026.
Is Nirvana Life Sciences' ROCE % too high?
Nirvana Life Sciences' current ROCE % is 0.00%.
How does Nirvana Life Sciences' ROCE % compare to VRTX and REGN?
Nirvana Life Sciences' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Nirvana Life Sciences's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current ROCE % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.